Brewin Dolphin Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$57K	Hold	96	–	–	0.01%	184
2022 Q1	$67K	Hold	96	–	–	0.01%	181
2021 Q4	$61K	Hold	96	–	–	0.01%	186
2021 Q3	$58.1K	Hold	96	–	–	0.01%	184
2021 Q2	$53.6K	Hold	96	–	–	0.01%	184
2021 Q1	$45.4K	Hold	96	–	–	0.01%	186
2020 Q4	$46.4K	Hold	96	–	–	0.01%	165
2020 Q3	$53.7K	Hold	96	–	–	0.01%	157
2020 Q2	$59.9K	Buy	+96	New	+$54.5K	0.01%	146

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brewin Dolphin Wealth Management's REGN Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2022 at 96 shares worth $57K. The position accounts for 0.01% of the portfolio, ranked #184.

Brewin Dolphin Wealth Management first reported a position in REGN in Q2 2020 and has held it in 9 quarters since. The position peaked at $67K in Q1 2022. 1,063 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Brewin Dolphin Wealth Management held 96 shares of Regeneron Pharmaceuticals worth $57K as of Q2 2022.
Brewin Dolphin Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2022.
Regeneron Pharmaceuticals made up 0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #184 holding.
Brewin Dolphin Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
Brewin Dolphin Wealth Management's Regeneron Pharmaceuticals position peaked at $67K in Q1 2022.
1,063 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.